DGAP-Adhoc: 4SC AG: Dr Daniel Vitt to step down as CDO/CSO and from the Management Board at the end of 2016 | Dr Frank Hermann promoted to CDO and Dr Roland Baumgartner to CSO


4SC AG  / Key word(s): Change of Personnel

21.10.2016 11:18

Disclosure of an inside information according to Article 17 MAR,
transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

4SC AG: Dr Daniel Vitt to step down as CDO/CSO and from the Management
Board at the end of 2016 |
Dr Frank Hermann promoted to CDO and
Dr Roland Baumgartner to CSO

Planegg-Martinsried, Germany, 21 October 2016 - 4SC AG (4SC, FSE Prime
Standard: VSC) today announced that Dr Daniel Vitt and the Supervisory
Board of 4SC have agreed that Daniel Vitt will step down as Chief
Development Officer and Chief Scientific Officer (CDO/CSO) as well as from
the Management Board of 4SC as of 31 December 2016. Dr Frank Hermann is
promoted to CDO and Dr Roland Baumgartner to CSO, in each case without
becoming a member of the Management Board. Both have already been members
of 4SC's management team.

4SC's Supervisory Board thanks Daniel Vitt for 19 years of valuable
Management Board service and contributions to the Company.


---------------------------------------------------------------------------

Information and Explanation of the Issuer to this News:

Dr Jason Loveridge, CEO of 4SC, commented: 'I would like to take this
opportunity to thank Daniel Vitt for his invaluable contribution to 4SC
over many years. His presence at the Company will be missed by all his
colleagues, and we would all like to wish him the very best for the future.

The senior team at 4SC now continues to evolve to address the later stage
clinical opportunities presented by resminostat and 4SC-202. I would like
to congratulate Roland Baumgartner, who has been with 4SC for 14 years in
Translational Pharmacology, and will provide continuity to our preclinical
work as our new CSO. Frank Hermann, who recently joined from Bristol-Myers
Squibb, will take the lead on drug development at 4SC as our new CDO to
better support our growing late-stage clinical program. These changes to
the senior team at 4SC help resource the Company for the continuing
clinical development of our lead epigenetic cancer compounds resminostat
and 4SC-202.'

About 4SC
4SC (www.4sc.com) is a biotech company dedicated to the research and
development of small-molecule drugs focused on epigenetic mechanisms of
action for the treatment of cancers with high unmet medical needs. These
drugs are intended to provide innovative treatment options for cancer
patients that are more tolerable and efficacious than existing therapies,
provide a better quality of life and offer increased life expectancy. The
Company's pipeline comprises promising products that are in various stages
of clinical development. 4SC's aim is to generate future growth and enhance
its enterprise value by entering into partnerships with pharmaceutical and
biotech companies. Founded in 1997, 4SC had 50 employees as of 30 June
2016. 4SC has been listed on the Prime Standard of the Frankfurt Stock
Exchange since December 2005.

Forward-looking information
Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. The forward-
looking statements contained herein represent the judgement of 4SC as of
the date of this press release. Such forward-looking statements are neither
promises nor guarantees, but are subject to a variety of risks and
uncertainties, many of which are beyond 4SC's control, and which could
cause actual results to differ materially from those contemplated in these
forward-looking statements. 4SC expressly disclaims any obligation or
undertaking to release any updates or revisions to any such statements to
reflect any change in its expectations or any change in events, conditions
or circumstances on which any such statement is based.

4SC Corporate Communications & Investor Relations
Wolfgang Güssgen, wolfgang.guessgen@4sc.com, +49 89 700763-73
Dr Anna Niedl, anna.niedl@4sc.com, +49 89 700763-66

MC Services
Katja Arnold, katja.arnold@mc-services.eu, +49 89 210228-40

The Ruth Group
Carol Ruth, cruth@theruthgroup.com, +1 646 536 7004

21.10.2016 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      4SC AG
              Am Klopferspitz 19a
              82152 Planegg-Martinsried
              Germany
Phone:        +49 (0)89 7007 63-0
Fax:          +49 (0)89 7007 63-29
E-mail:       public@4sc.com
Internet:     www.4sc.com
ISIN:         DE000A14KL72
WKN:          A14KL7
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated
              Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
              Stuttgart, Tradegate Exchange
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------